+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 100Years
All Genders
ID04851015

Comparing Low Dose and Standard Dose Trimethoprim-Sulfamethoxazole to Treat Pneumocystis Jirovecii Pneumonia in Adults

Led by Todd C. Lee MD MPH FIDSA · Updated on 2026-02-20

416

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Pneumocystis jirovecii pneumonia PCP is a serious fungal infection that mainly affects people with weakened immune systems, such as those with HIV, organ transplants, cancer, or on immunosuppressive treatments. This research aims to compare the effects and safety of two different doses of the drug trimethoprim-sulfamethoxazole TMP-SMX to find the best treatment approach for PCP. The trial is a Phase III randomized, placebo-controlled study designed to address concerns about the side effects seen with the current standard dose of TMP-SMX. Participants will receive either a reduced dose of TMP-SMX at 10 mgkgday or the standard dose at 15 mgkgday. The medication can be given orally or through an intravenous line, based on the treating teams choice. All doses will be adjusted for factors like obesity and kidney function. To maintain the studys blindness, patients in the reduced dose group will receive placebo tablets or solutions to mimic the higher dose, and those in the standard dose group will receive the full dose plus a masked portion to match the study design. During the study, participants will be closely monitored for a range of outcomes including death, need for advanced respiratory support, severe side effects, changes in therapy, and length of hospital stay, all assessed within 30 days. Researchers will evaluate these measures to understand the safety and effectiveness of the lower dose compared to the standard dose. The trial includes detailed assessments and follows patients over this period to capture important health changes and treatment responses.

CONDITIONS

Brief Title

Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia

Research Team

B

Babykumari Chitramuthu, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here